• Inositol hexakisphosphate kinase 1 (IP6K1) knockout mice display lower inorganic polyphosphate levels in platelets.
Introduction
Inorganic polyphosphate (polyP) consists of linear polymers of orthophosphate moieties linked by phosphoanhydride bonds. This high energy anionic molecule is found in all organisms, from archaea to mammals, varying in chain length and physiological function. 1 PolyP of chain length of 60 to 100 phosphate units is present in dense granules of mammalian platelets at a concentration of ;130 mM (expressed in terms of phosphate monomers). 2 Platelet polyP regulates the blood clotting cascade at various points in the extrinsic, intrinsic, and common pathways. 3 PolyP released from platelet dense granules initiates clotting via the contact pathway by acting as an anionic surface to trigger factor XII cleavage. 4, 5 Activation of factor XI by thrombin and autoactivation by factor XIa is accelerated in the presence of platelet length polyP. 3, 6 At the beginning of the common pathway, polyP accelerates the conversion of factor V to Va by both thrombin and factor Xa. 7 As activated factor Va converts prothrombin to thrombin, platelet-derived polyP causes a localized thrombin burst at the clot site. The rapid formation of factor Va antagonizes the anticoagulant activity of tissue factor pathway inhibitor. 7, 8 An additional procoagulant function of polyP downstream of thrombin generation is the incorporation of polyP into fibrin clots, resulting in increased fibrin fiber thickness and altered fibrin distribution within the clot. 9, 10 Fibrin clots containing polyP dissolve more slowly compared with clots formed in the absence of polyP. 9, 10 The presence of polyP in the clot attenuates fibrinolysis by blocking the binding of tissue type plasminogen activator or plasminogen to fibrin. PolyP also slows fibrinolysis as a consequence of increased thrombin generation by enhancing the activity of thrombin-activatable fibrinolysis inhibitor. 7 Platelet activation by extracellular histones is potentiated in the presence of polyP. 11 It was recently shown that platelet a-granules also contain polyP at 500-fold lower levels than dense granules. 12 PolyP in a-granules is bound to von Willebrand factor (vWF) and enhances vWF-dependent platelet aggregation. PolyP also acts as a proinflammatory agent, as demonstrated by stimulation of bradykinin generation in human plasma by synthetic polyP 4 and by polyP derived from acid-rich granules of mast cells. 13 In budding yeast, polyP accumulates predominantly in vacuoles and is synthesized from ATP by the vacuolar membrane transporter chaperone (VTC) complex.
14 Yeast polyP levels are dependent on the presence of another family of high-energy phosphate-rich small molecules called inositol pyrophosphates. 15, 16 These consist of an inositol ring substituted with monophosphate and diphosphate groups. The inositol pyrophosphate 5-diphosphoinositol pentakisphosphate (5-IP 7 ) is synthesized from inositol hexakisphosphate (IP 6 ) by IP 6 kinases (IP6Ks). The VIP1 family of enzymes converts 5-IP 7 to 1,5 bis-diphosphoinositol tetrakisphosphate (IP 8 ). 17, 18 In an alternate pathway, VIP1 converts IP 6 to 1-IP 7 , which is then phosphorylated by IP6Ks to generate IP 8 . 19 Saccharomyces cerevisiae lacking the IP 6 kinase KCS1 have undetectable levels of inositol pyrophosphates and substantially reduced levels of polyP. 20, 21 It is therefore believed that the cellular levels of inositol pyrophosphates and polyP are metabolically linked. 22 Mammals have 3 isoforms of IP 6 kinases, IP6K1, IP6K2, and IP6K3, 23, 24 and 2 isoforms of VIP1. 25, 26 Ip6k1 knockout (Ip6k1 2/2 ) mice display lower body weight, reduced insulin levels, and defective spermatogenesis compared with wild-type (WT) littermates. 27 Mouse embryonic fibroblasts (MEFs) isolated from Ip6k1 2/2 embryos have 70% reduced IP 7 levels compared with WT MEFs. To determine whether the link between inositol pyrophosphate and polyP levels is conserved in mammals, we measured platelet polyP levels in Ip6k1 2/2 mice. We observe a significant reduction in platelet polyP concomitant with altered clotting parameters and clot architecture in these mice. In vivo studies indicate that the absence of IP6K1 and subsequent decrease in platelet polyP reduces the susceptibility of these animals to pulmonary thromboembolism. Our study therefore highlights a novel role for mammalian IP6K1, acting upstream of polyP, and thereby indirectly regulating hemostasis.
Methods
All reagents, unless otherwise stated, were procured from Sigma-Aldrich (St. Louis, MO). All procedures were at room temperature unless specified otherwise.
Animals
The Ip6k1 gene knockout mouse was generated as previously described 27 and back-crossed into the C57BL/6 strain for 7 generations. Ip6k1 heterozygous mice were bred to generate littermate WT and Ip6k1 2/2 mice. All mice used in this study were 8-to 20-week-old age-matched males, unless specified otherwise. They were housed in the animal facility at the Centre for Cellular and Molecular Biology, Hyderabad, or the Centre for DNA Fingerprinting and Diagnostics animal facility located within the premises of Vimta Labs, Hyderabad. Animals were maintained as per guidelines provided by the Committee for the Purpose of Control and Supervision of Experiments on Animals, Ministry of Environment and Forests, Government of India. All animal experiments were approved by the Institutional Animal Ethics Committees of the respective animal facilities.
Platelet preparation
Mice were anesthetized by inhalation of an isofurane:oxygen (3:97) mixture or by an intraperitoneal injection of ketamine (20 mg/kg body weight) and xylazine (20 mg/kg body weight) and subjected to retro-orbital blood sampling. Three hundred microliters of blood was collected into 3.2% trisodium citrate (blood to anticoagulant ratio 9:1). Platelet-rich plasma (PRP), obtained by differential centrifugation of the citrated blood at 200g for 2 minutes followed by 100g for 2 minutes, was directly used in some assays. Washed platelets were prepared by centrifuging the PRP at 2500g for 4 minutes in the presence of prostaglandin I 2 (PGI 2 , 500 nM; Calbiochem, Billerica, MA) to prevent platelet activation. Platelets were resuspended in 50 mL modified N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acidTyrode's buffer (140 mM NaCl, 2 mM KCl, 12 mM NaHCO 3 , 0.3 mM NaH 2 PO 4 , 1 mM MgCl 2 , 5.5 mM glucose, and 5 mM N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid, pH 6.7). In some cases, platelets were pelleted in the absence of PGI 2 , and the supernatant was used as plateletpoor plasma (PPP).
IP6K1 detection
IP6K1 expression in platelets and megakaryocytes was monitored as described in supplemental Methods on the Blood website.
Platelet polyP detection
PolyP in platelet acidic extracts was quantified by measuring orthophosphate (Pi) released on treatment with the S cerevisiae exopolyphosphatase PPX1, as described in supplemental Methods.
Functional analysis of platelets
Thrombin-stimulated P-selectin surface expression, adenosine 5'-diphosphate (ADP)-stimulated surface expression of integrin aIIbb3, and platelet serotonin levels were measured by flow cytometry. Platelet ultrastructure was examined by transmission electron microscopy. Platelet aggregation was determined spectrophotometrically by monitoring an increase in transmission. These procedures are described in detail in supplemental Methods.
Clot turbidimetry
Washed platelets prepared in the absence of PGI 2 were activated with ADP (200 mM) at 37°C for 30 minutes and centrifuged at 18 000g for 15 minutes at 4°C. Platelet releasates in the supernatant were mixed with an equal volume of the corresponding PPP in 96-well flat bottom plates. Clotting was induced by recalcification with CaCl 2 (5 mM) in a final reaction volume of 150 mL, and the change in turbidity was monitored at 405 nm in a microplate reader (SpectraMax Plus384; Molecular Devices, Sunnyvale, CA).
Clot ultrastructure
Platelet releasates were prepared as described in the Clot turbidimetry section. PPP was supplemented with 5% Alexa Fluor 488-conjugated fibrinogen (Invitrogen, Carlsbad, CA). Fifty microliters of this PPP was mixed with 50 mL platelet releasate and 49,6-diamidino-2-phenylindole (DAPI; 40 mM) in a coverglass bottom dish. Clotting was initiated by recalcification (CaCl 2 , 5 mM) in a final volume of 150 mL and incubated in a dark humidified chamber for 30 minutes. Clot architecture was imaged by confocal fluorescence microscopy (LSM 510 META; Carl Zeiss, Jena, Germany) with a 633/1.4 NA oil objective (multiphoton laser Ex 760 nm , and Em 535-590 nm for DAPI; argon laser Ex 488 nm, and Em 500-550 nm for Alexa Fluor 488). Four different fields were imaged for each clot, and ImageJ software (Analyze Particles plugin) was used to determine fiber density, which is the number of fibers crossing a 100-mm line averaged over 3 different positions in each image. PolyP detection by DAPI staining is described in supplemental Methods. The relative fluorescence intensity of DAPI quantified using ImageJ reflected the amount of polyP entangled in the clot. In some cases, the PPP was supplemented with polyP45 (50 mM; Sigma-Aldrich) or IP 7 (100 mM) prior to the addition of platelet releasate.
In vivo clotting analyses
Tail bleeding time and pulmonary thromboembolism were monitored by standard procedures, as described in supplemental Methods.
Data analysis
All data were plotted and analyzed using GraphPad Prism (La Jolla, CA). P , .05 was considered statistically significant.
Results
Reduced polyP levels in Ip6k1 2/2 platelets
To investigate the link between inositol pyrophosphates and polyP in mammalian platelets, we first tested for the presence of IP6K1 in mouse platelets by immunoblotting with an IP6K1-specific antibody. We observe that extracts from WT mouse platelets contain IP6K1, but there is no detectable band in Ip6k1 2/2 platelets ( Figure 1A ). We also conducted immunofluorescence analysis of mouse bone marrow sections to look for the presence of IP6K1 in platelet progenitor megakaryocytes. Although IP6K1 was detectable in the cytoplasm of WT megakaryocytes, no immunostaining was observed in Ip6k1 2/2 bone marrow sections ( Figure 1B ).
As MEFs derived from IP6K1 knockout embryos show a 70% reduction in intracellular IP 7 , 27 it is likely that Ip6k1 2/2 platelets also have reduced amounts of inositol pyrophosphates. Because inositol pyrophosphate levels correlate with polyP levels in yeast, 20, 21 we examined platelets isolated from WT and Ip6k1 2/2 mice for the presence of polyP. Although WT platelets displayed a wide variation in levels of polyP, there was a significant overall reduction in polyP in Ip6k1 2/2 platelets ( Figure 2A ). In yeast, loss of the IP 6 kinase KCS1 leads to increased ATP and reduced ADP levels. 28 We therefore measured ADP and ATP levels in platelet extracts from WT and Ip6k1 2/2 mice and found no significant difference between the 2 sets of platelets ( Figure 2B ). These data show that the loss of IP6K1 in platelets leads to a reduction in polyP, as seen in yeast, but no change in ADP or ATP, both of which are important modulators of platelet function.
Analysis of platelet function
We wondered whether the reduction in polyP levels in Ip6k1
platelets results in an alteration of platelet characteristics in these mice. Analysis of hematologic parameters in WT and Ip6k1 2/2 mice revealed no difference in platelet count between these groups (Table 1) . Other blood parameters, including red and white cell counts, hematocrit, and hemoglobin concentration, were also found to be normal in Ip6k1 2/2 mice. Platelet size, ascertained by flow cytometry measurement of forward scatter in washed and fixed platelets, was found to be comparable in WT and Ip6k1 2/2 mice ( Figure 3A) . We observed no morphological difference between WT and Ip6k1 2/2 platelets by transmission electron microscopy ( Figure 3B ). Whole mount transmission electron microscopy, which is routinely used to detect platelet dense granules, revealed no obvious alteration in the appearance and number of these structures in Ip6k1 2/2 platelets ( Figure 3B ).
We also monitored activation of WT and Ip6k1 2/2 platelets by 2 agonists: thrombin and ADP. Thrombin-mediated activation was examined by measuring the levels of surface P-selectin, a cell adhesion molecule released from secretory a-granules ( Figure 3C ).
No alteration in P-selectin surface expression in Ip6k1 2/2 platelets implies that IP6K1 does not influence platelet a-granule content or its thrombin-stimulated release. ADP stimulation of platelets was tested by measuring binding of fluorescently labeled fibrinogen to washed platelets treated with ADP. Fibrinogen binding to platelet surface integrin a IIb b 3 reflects platelet activation and is critical for platelet aggregation. We observe no difference in the extent of fibrinogen binding to activated WT or Ip6k1 2/2 platelets ( Figure 3D ), indicating that both sets of platelets respond normally to ADP stimulation. Following activation by different agonists, platelets adhere and aggregate to form a plug at the site of injury, leading to primary hemostasis. Platelet aggregation on thrombin stimulation was measured in washed platelets isolated from WT or Ip6k1 2/2 mice. We observe a significant decrease in the extent of aggregation of Ip6k1 2/2 platelets ( Figure 3E ). Platelets aggregate using fibrinogen and vWF as connecting agents. Although fibrinogen binding to integrin a IIb b 3 is normal in Ip6k1 2/2 platelets, it is possible that vWF function is compromised due to lowered levels of polyP. 12 Trafficking of cargo to dense granules is dependent on the adaptor protein complex AP3, the function of which is compromised in IP6K1 knockout MEFs. 29 It is possible that the decrease in platelet polyP in Ip6k1 2/2 mice is secondary to an AP3-dependent trafficking defect. Serotonin is a major constituent of platelet dense granules, and defective AP3-mediated trafficking leads to a reduction in platelet serotonin levels. 30 We therefore measured serotonin levels in platelets isolated from WT and Ip6k1 2/2 mice by flow cytometry analysis of fixed platelets. No difference in serotonin content was observed between WT and Ip6k1 2/2 -derived platelets ( Figure 3F ), implying that the polyP deficiency in Ip6k1 2/2 platelets is not due to defective AP3 mediated trafficking to dense granules, but most likely results from a direct metabolic link between IP 7 and polyP. 21, 22 Altered clotting parameters in Ip6k1 2/2 mice
Our data thus far have established a molecular link between the presence of IP6K1 and polyP in platelets. PolyP influences plasma P values are from a 2-tailed Student t test (*P # .05; n.s., not significant, P . .05). clotting upstream of thrombin generation. 3 We therefore used ADP instead of thrombin to activate and degranulate washed platelets and generate releasates used in subsequent analyses to measure the influence of polyP on clotting. Platelet-length polyP have been shown to reduce clotting time on the addition of excess Ca 21 to citrated plasma in vitro. 7, 8 We slightly modified this assay by adding platelet releasates from WT and Ip6k1 2/2 mice to their autologous citrated PPP, prior to recalcification and clot turbidity measurement ( Figure 4A ). Following recalcification, plasma fibrinogen is converted to insoluble fibrin monomers, which polymerize to form longer protofibrils. These protofibrils aggregate laterally to form a fibrin clot, which is reflected as an increase in turbidity measured at 405 nm. We measured the lag time after recalcification at which an exponential increase in absorbance, reflecting protofibril aggregation, is observed. 31 The end of this exponential phase, at which the absorbance reading begins to plateau, was measured as the clotting time. Both the lag time and total clotting time are significantly lengthened in Ip6k1 Prior studies have demonstrated that polyP binds to fibrinogen and soluble fibrin and is incorporated into the polymerized fibrin clot. 9, 10 The presence of polyP within a clot alters its architecture, reducing clot homogeneity and changing fibrin distribution within the clot. 10 To examine whether the reduction in platelet polyP levels in Ip6k1 2/2 mice leads to altered clot architecture, we prepared clots by recalcifying a mixture of PPP and clarified platelet releasate, spiked with fluorescently labeled fibrinogen, and stained these clots with DAPI to detect polyP. Clots examined by confocal microscopy revealed a homogenous web-like clot architecture in Ip6k1 2/2 samples, whereas thicker fibrin fibrils and tight fibrin aggregates interspersed with large pores were observed in WT clots ( Figure 5A ). We quantified the extent of clot homogeneity by measuring the average fiber density and observed a significant increase in the number of fibers per unit length in Ip6k1 2/2 -derived clots compared with WT ( Figure 5B ). WT clots also stained positive for the presence of polyP, with maximal staining in the knots ( Figure 5A ), whereas there was a fourfold reduction in DAPI staining of Ip6k1 2/2 -derived clots ( Figure 5C ).
This difference in clot architecture between polyP-containing and -deficient clots derived from mice reflects prior studies conducted in vitro, which reported a similar difference in clots formed using purified fibrinogen in the presence or absence of polyP. 9, 10 We therefore predicted that adding back polyP during clot formation in Ip6k1 2/2 samples would result in Ip6k1 2/2 -derived clots that resemble the architecture of WT clots. Indeed, incorporation of polyP (average chain length, 45) during clot formation in WT and Ip6k1 2/2 samples resulted in thickening of fibrils, an increased number of knots, and reduction in fiber density, thus eliminating the differences observed between WT and Ip6k1 2/2 clots ( Figure 5A -B).
It is possible that IP 7 plays a direct role in clot structure formation and that the difference between WT and Ip6k1 2/2 clots arises directly due to a reduction in IP 7 levels rather than lowered polyP.
To address this possibility, we added IP 7 during WT and Ip6k1
2/2
clot formation and noted a loss of fibrin aggregates and homogenous clot architecture in both samples ( Figure 5A ). The presence of IP 7 therefore does not rescue the structural alteration of Ip6k1
clots, whereas adding polyP results in Ip6k1 2/2 clots that closely resemble the architecture of WT clots. These data indicate that the effect of inositol pyrophosphates on clotting is not direct but instead reflects the metabolic link between inositol pyrophosphates and polyP synthesis.
Hemostasis defects in Ip6k1 2/2 mice Platelets derived from patients with d storage pool diseases (dSPDs), characterized by a defect in dense granule formation or function leading to bleeding diathesis, have substantially lowered levels of polyP compared with the general population. 32 Delayed in vitro clot formation in such patient samples was shortened on addition of polyP. 4 The loss of polyP has therefore been suggested to be a contributor to bleeding diathesis observed in dSPD patients. As Ip6k1 2/2 mice exhibit a similar decrease in platelet polyP, they too are likely to display bleeding diathesis. We therefore determined the bleeding time of WT and Ip6k1 2/2 mice by amputation of the tail tip. We note a significant lengthening of average bleeding time in Ip6k1 2/2 compared with WT mice ( Figure 6A ). Cessation of tail bleeding is primarily due to platelet plug formation as a result of platelet aggregation. The prolonged bleeding time in Ip6k1
mice reflects reduced aggregation of Ip6k1 2/2 platelets in vitro ( Figure 3E ) and concurs with the recent finding that cleavage of polyP bound to vWF leads to lower platelet aggregation. 12 Our findings therefore support a role for polyP in primary hemostasis in the whole animal.
To examine the effect of reduced polyP on hemostasis in vivo, we used a pulmonary thrombosis model. Infusion of polyP into the vasculature has been shown to induce lethal pulmonary thromboembolism in mice. 4 More recently, it was shown that mice treated with a cationic polymer that scavenges polyP are protected against lethal pulmonary thrombosis 33 and display attenuated venous and arterial thrombosis. 34 WT and Ip6k1 2/2 mice were challenged with a high dose of intravascular ADP to induce pulmonary thromboembolism, and animals were monitored for respiratory pattern and survival. Although fewer WT mice survived this challenge ( Figure 6B ), those that lived longer than 30 minutes exhibited signs of severe respiratory distress and were immobile. In contrast, the majority of Ip6k1 2/2 mice survived and were active following the challenge, displaying uniform breathing. Lung sections from WT and Ip6k1 2/2 mice that survived the challenge were examined for the presence of occluded vessels. We noted a higher degree of occlusion in large pulmonary vessels in WT compared with Ip6k1
mice, reflecting the difference in their breathing pattern ( Figure 6C ). Our results clearly indicate a role for IP6K1 in maintaining in vivo hemostasis by influencing platelet polyP levels.
Discussion
Our study identifies IP6K1 as a novel contributor to the maintenance of hemostasis in mammals. Specifically, we showed that platelets derived from mice lacking IP6K1 have reduced levels of polyP, resulting in longer clotting time and altered clot ultrastructure in vitro. Because we are able to restore the architecture of clots derived from Ip6k1 2/2 mice by adding polyP but not by adding IP 7 , we can infer that inositol pyrophosphates do not influence hemostasis directly but via polyP levels. As platelet polyP plays a major role in coagulation, Ip6k1 2/2 mice display longer bleeding time and are protected from in vivo thrombosis. We demonstrated that platelets express IP6K1, and a recent proteomic analysis of human platelets documented the expression of VIP2, 35 an enzyme that can convert 5-IP 7 to IP 8 , implying that both inositol pyrophosphates, IP 7 and IP 8 , are synthesized in platelets. The molecular mechanism linking the absence of IP6K1 to a reduction in platelet polyP is unclear. Evidence of a positive correlation between the levels of inositol pyrophosphates and polyP in yeast suggests that the same link may be conserved in mammals. S cerevisae lacking the IP 6 kinase gene KCS1 exhibit dramatically reduced levels of inositol pyrophosphates and low to undetectable levels of polyP. [20] [21] [22] When catalytically active but not inactive mouse IP6K1 was expressed in kcs1D yeast, polyP levels were restored, implying that inositol pyrophosphate synthesis by IP 6 kinases is crucial to maintain the intracellular polyP pool. 21 IP 7 and IP 8 may contribute to polyP synthesis or stability via a direct metabolic link 22 or indirectly by pyrophosphorylating proteins involved in polyP synthesis or degradation. 36, 37 Inositol pyrophosphates have been shown to regulate phosphate uptake into cells, control intracellular levels of ATP, 28 and are thought to be metabolic messengers that maintain cellular energy homeostasis. 39 As polyP is a store of phosphate and energy, its synthesis is believed to be linked to phosphate entry and to ATP levels within the cell. 40 However, we observe no changes in platelet ATP or ADP levels in Ip6k1 2/2 mice, suggesting that the influence of inositol pyrophosphates on platelet polyP is independent of adenine nucleotide levels. Although platelet polyP is not thought to be an energy store, our data suggest that the metabolic link between inositol pyrophosphates and polyP is evolutionarily conserved across all eukaryotes from yeast to mice, even in specialized cell types such as platelets. The enzyme responsible for polyP synthesis in mammals has not yet been identified. In S cerevisae, subunit 4 of the VTC complex was identified a few years ago as a polyP synthase, but no paralogs of this enzyme exist in higher eukaryotes. 14 The amoeba Dictyostelium discoideum, which has high levels of polyP, possesses 2 enzymes responsible for polyP synthesis: a homolog of the bacterial polyphosphate kinase, DdPPK1, 41 and an actin-like polyP kinase, DdPPK2. 42 Mammals do not possess genes homologous to the bacterial polyP kinases, but proteins similar to actin-like polyP kinases are present, 43 and polyP synthesis in mammals is thought to be via an enzyme similar to DdPPK2. However, because our data show that the metabolic link between inositol pyrophosphates and polyP is conserved in yeast and mammals, it is possible that the mechanism for polyP synthesis in mammals is not dissimilar from that in yeast.
Although polyP was identified in platelet-dense granules almost a decade ago, 2 and there have been significant advances in our understanding of its various effects on clotting, 3 we are yet to fully understand the role of platelet polyP in an in vivo context. Studies conducted thus far have focused on understanding the effects of polyP on various clotting parameters such as clotting time, fiber density, factor V activation, factor XI activation, and abrogation of TFPI activity in isolated assays. Ip6k1 2/2 mice, which display altered hemostasis due to lowered platelet polyP levels, serve as a unique model to study the combined effects of polyP at multiple stages of the clotting cascade. Other functions in which polyP participates include cancer cell proliferation and metastasis, [44] [45] [46] bone mineralization, 47 and energy metabolism. 48 Ip6k1 2/2 mice could also serve as a model to shed light on the mechanism and physiological significance of these and other functions of polyP.
Owing to its strong procoagulant properties, platelet polyP plays an important role in many clinical and pathological conditions. The clotting time of plasmas derived from patients of severe hemophilia A or B, or patients receiving the anticoagulant warfarin, was shortened by the addition of polyP. 49 PolyP also reversed a defect in vWF-dependent platelet agglutination in patients of type I von Willebrand disease. 12 Hermansky-Pudlak syndrome is a form of dSPD in which patients display dysfunctional biogenesis of lysosomerelated organelles including platelet dense granules, leading to prolonged bleeding time in addition to other clinical features such as albinism. Lengthened plasma clotting time in Hermansky-Pudlak syndrome patients can be rescued by the addition of polyP. 4 The prolonged bleeding time in Ip6k1 2/2 mice may reflect a novel form of dSPD, attributed only a specific loss of polyP, with no alteration in the levels of other dense granule components. Thromboembolism can lead to fatal pathological conditions including stroke, pulmonary embolism, deep vein thrombosis, and myocardial infarction. Our data demonstrating the resistance of Ip6k1 2/2 mice to ADP-induced pulmonary thromboembolism reveals that inositol pyrophosphates are key players in maintaining hemostasis. We speculate that specific inhibitors of IP 6 kinases 50 may function as antithrombotic agents. As IP 6 kinases participate in several physiological functions, including insulin secretion, maintenance of body weight, and male fertility, 27 further studies will be required to determine the pharmacological impact of reduced inositol pyrophosphate synthesis in the control of thrombosis. provided assistance for mouse experiments; R.M. synthesized and purified IP 7 and PPX; S.K. provided valuable inputs and support; S.G. and R.B. designed the research and wrote the paper; and S.G., D.S., K.S., B.J.L., R.M., S.K., and R.B. read and agreed on the final version of the manuscript. Conflict-of-interest disclosure: The authors declare no competing financial interests.
